Stocks Health care MCRB
NASDAQ · Health careSeres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. brought in $1.9M of revenue over the twelve months to June 30, 2026. It posted a net loss of $22.5M. Operating cash flow minus capital spending left $865K of free cash flow in fiscal 2025. At June 30, 2026 it held $15.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Seres Therapeutics, Inc.
- Net worth
- Seres Therapeutics, Inc. has a market value (market cap) of $16.2M at the latest share price, and shareholders' equity of $34.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- Over the 12 months to June 30, 2026: revenue $1.9M, net loss $22.5M.
- Cash flow
- In fiscal 2025 operations brought in $1.1M of cash; after $252K of capital spending, free cash flow was $865K.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Seres Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Seres Therapeutics, Inc. does
Seres Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MCRB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $789K | $5.7M | $0.64 | $865K |
| 2024 | $0 | $136K | $0.00 | -$149M |
| 2023 | $0 | -$113.7M | -$17.77 | -$125.3M |
| 2022 | $7.1M | -$250.2M | -$46.12 | -$238.6M |
| 2021 | $144.9M | -$65.6M | -$14.38 | -$2.9M |
| 2020 | $33.2M | -$89.1M | -$22.36 | -$94.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MCRB ranks in Health care
Latest SEC filings
What Seres Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 5, 2026
- August 5, 2026
- August 4, 2026
- July 9, 2026
- July 8, 2026
- July 8, 2026
- June 5, 2026
- June 1, 2026
- May 5, 2026
What is MCRB worth? A DCF from its reported cash flow
Insider trades
What the people running Seres Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.2K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 17, 2026 | DesRosier ThomasSee Remarks | Soldpre-planned (10b5-1) | 82 | $373.1 |
| August 17, 2026 | Henn Matthew RSee Remarks | Soldpre-planned (10b5-1) | 81 | $368.6 |
| August 17, 2026 | Shaff Eric D.Director | Soldpre-planned (10b5-1) | 263 | $1.2K |
| August 17, 2026 | Brady KellySee Remarks | Soldpre-planned (10b5-1) | 64 | $291.2 |
| August 15, 2026 | DesRosier ThomasSee Remarks | Exercised options | 245 | - |
| August 15, 2026 | Henn Matthew RSee Remarks | Exercised options | 238 | - |
| August 15, 2026 | Shaff Eric D.Director | Exercised options | 722 | - |
| August 15, 2026 | Brady KellySee Remarks | Exercised options | 181 | - |
Who owns MCRB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nestlé S.A.13D, may seek influence with 1 related filers | 14.29% | October 2, 2024 |
Largest institutional holders
Insiders
5 insiders reported holding 45,847 shares in total, about $73.8K at the last price.
| Holder | Shares |
|---|---|
| Shaff Eric D.Director | 12,499 |
| Brady KellySee Remarks | 8,679 |
| Young Teresa L.See Remarks | 8,557 |
| DesRosier ThomasSee Remarks | 8,117 |
| Henn Matthew RSee Remarks | 7,995 |
Questions about MCRB
What does Seres Therapeutics, Inc. do?
Seres Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as MCRB. Its shares trade on NASDAQ under the ticker MCRB.
What is Seres Therapeutics, Inc.'s net worth?
Seres Therapeutics, Inc. has a market value (market cap) of $16.2M at the latest share price, and shareholders' equity of $34.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Seres Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $22.5M on revenue of $1.9M.
How much revenue does Seres Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Seres Therapeutics, Inc. reported revenue of $1.9M.
When did Seres Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
When is Seres Therapeutics, Inc.'s next earnings report?
Seres Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare MCRB with
Follow MCRB
Get an email when Seres Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Seres Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.